



# 7<sup>th</sup> Annual Dermatology Summit

Ted White, President & CEO

January 12, 2020



# DISCLAIMER

---

Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica's own internal estimates and research. While Verrica believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. While Verrica believes its internal research is reliable, such research has not been verified by any independent source.

This presentation contains forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future conditions. All statements other than statements of historical facts contained in this presentation, including statements regarding future results of operations and financial position, business strategy, current and prospective product candidates, planned clinical trials and preclinical activities, product approvals, degree of market acceptance of approved products, research and development costs, current and prospective collaborations, timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated product candidates, are forward-looking statements. The words "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The information in this presentation, including without limitation the forward-looking statements contained herein, represent our views as of the date of this presentation. Although


we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. The forward-looking statements in this presentation involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, our reliance on third parties over which we may not always have full control, and other risks and uncertainties that are described in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the U.S. Securities and Exchange Commission (SEC) on March 7, 2019, and our other filings made with the SEC. New risk factors and uncertainties may emerge from time to time, and it is not possible to predict all risk factors and uncertainties. There can be no assurance that the opportunity will meet your investment objectives, that you will receive a return of all or part of such investment. Investment results may vary significantly over any given time period. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. We recommend that investors independently evaluate specific investments and strategies.



# TWO OF THE LARGEST UNMET NEEDS IN DERMATOLOGY

## Molluscum

US Prevalence of **~6 million<sup>(1)</sup>** with **~1 million diagnosed annually<sup>(2)</sup>**



## Common Warts

US Prevalence of **~22 million<sup>(3)</sup>** with **~1.5 million diagnosed annually<sup>(4)</sup>**



(1) Prevalence in the US of 5.1% to 11.5% in children aged 0-16 years. (Fam Pract. 2014 Apr;31(2):130-6). US Census estimates ~69.4MM children aged 0 to 16 years in 2016.

(2) IQVIA projected dataset for 12 months ending October 2017

(3) IMS National Disease and Therapeutic Index (NDTI) Rolling 5 Years Ending June 2016. Nguyen et al, Laser Treatment of Nongenital Verrucae A Systemic Review. JAMA Dermatology. 2016; 152(9): 1025-1033

(4) IQVIA Anonymous Longitudinal Patient Level Data (APLD) for 12 months ending September 2018

# OUR PRODUCT PORTFOLIO

	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	NDA SUBMISSION	NEXT EXPECTED MILESTONE
<b>Molluscum Contagiosum</b>						PDUFA Goal Date: July 13, 2020
<b>Common Warts</b>						Initiate pivotal Phase 3 trials in 1Q 2020
<b>External Genital Warts</b>						Topline Phase 2 results in 2H 2020
<b>Plantar Warts<sup>(1)</sup></b>						Initiate Phase 2 trial Mid 2020

(1) Phase 2 ready assuming leverage of data from VP-102.

**We retain exclusive, royalty-free rights to our product candidates across all indications globally**

VP-102

VP-103

# YCANTH (VP-102) IS A PROPRIETARY DRUG-DEVICE COMBINATION OF CANTHARIDIN ADMINISTERED THROUGH OUR SINGLE-USE PRECISION APPLICATOR

**GMP-controlled new formulation**  
of 0.7% w/v cantharidin


- Consistent and shelf-stable

**Single-use applicator** to reduce cross-contamination and allow for more effective application of drug by HCP

**Visualization agent** to identify treated lesions


**Bittering agent** to deter oral ingestion

**Clinician administered, In-Office Procedure**




# PHASE 3 STUDIES IN MOLLUSCUM DEMONSTRATE STATISTICALLY SIGNIFICANT EFFICACY ON PRIMARY ENDPOINT OF COMPLETE CLEARANCE

## Percentage of Patients With Complete Clearance of Molluscum Lesions at Day 84 (ITT Population)




# PHASE 3 STUDIES IN MOLLUSCUM DEMONSTRATE STATISTICALLY SIGNIFICANT EFFICACY ON PERCENT REDUCTION OF LESIONS
















# YCANATH (VP-102) DEMONSTRATED CLINICALLY MEANINGFUL EFFICACY ON PRIMARY ENDPOINT OF COMPLETE CLEARANCE IN COVE-1 STUDY IN COMMON WARTS



# SIGNIFICANT RECENT AND EXPECTED MILESTONES

DATE	EVENT
 1Q 2019	Positive topline results from two pivotal Phase 3 trials in molluscum
 2Q 2019	Positive topline results from Phase 2 trial in common warts
 2Q 2019	Initiate Phase 2 trial in external genital warts
 3Q 2019	VP-102 NDA submission in molluscum
 4Q 2019	FDA acceptance of VP-102 NDA submission in molluscum
 4Q 2019	VP-103 IND submission in plantar warts
 1Q 2020	Initiate pivotal Phase 3 trials in common warts
 Mid 2020	Initiate Phase 2 trial in plantar warts
 2H 2020	YCANTH PDUFA Goal Date July 13, 2020 in molluscum
 2H 2020	Topline results from Phase 2 trial in external genital warts
 2H 2020	Commercial launch of YCANTH for molluscum